Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
Carlos King-Ho WongXi XiongKristy Tsz Kwan LauCeline Sze Ling ChuiFrancisco Tsz Tsun LaiXue LiEsther Wai Yin ChanEric Yuk Fai WanIvan Chi Ho AuBenjamin John CowlingCheuk Kwong LeeIan Chi Kei Ck WongPublished in: BMC medicine (2022)
No significant association between delayed second dose of BNT162b2 or CoronaVac and all-cause mortality, ED visit, and unscheduled hospitalization was observed in the present cohort. Regardless of the recommended or delayed schedule for SARS-CoV-2 vaccination, a second dose of both vaccines should be administered to obtain better protection against infection and serious disease. The second dose should be administered within the recommended interval following the manufacturer's product information, until further studies support the benefits of delaying vaccination outweighing the risks.